State-of-the-Art PaperAcute Coronary Syndrome: Emerging Tools for Diagnosis and Risk Assessment
Under an Elsevier user license
open archive
Key Words
acute coronary syndrome
diagnosis
myocardial infarction
risk stratification
Abbreviations and Acronyms
ACS
acute coronary syndrome
CAD
coronary artery disease
CK-MB
creatine kinase-myocardial bound
CMR
cardiac magnetic resonance
CRP
C-reactive protein
CTA
computed tomography angiography
ECG
electrocardiographic
GDF
growth differentiation factor
HRT
heart rate turbulence
HRV
heart rate variability
MDCT
multidetector computed tomography
MI
myocardial infarction
MPI
myocardial perfusion imaging
NP
natriuretic peptide
NSTE-ACS
non–ST-segment elevation acute coronary syndrome
STEMI
ST-segment elevation myocardial infarction
Cited by (0)
Dr. Scirica has received research grants via the TIMI Study Group and Brigham and Women's Hospital from CV Therapeutics, Novartis, AstraZeneca, Daiichi-Sankyo, Merck, Johnson and Johnson, Bayer Healthcare, and Bristol-Myers Squibb. He has received honoraria for educational presentations from CV Therapeutics, Novartis, Merck, and Schering-Plough; and has served as a consultant for AstraZeneca, Novartis, CV Therapeutics, Congentus, Shionegi, and Gilead Sciences.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.